|
MechanismCD40L stimulants |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1b Study of OPT101 in Patients With Type 1 Diabetes
Phase 1b designed to assess safety, pharmacokinetics, immunological and clinical effects of multiple ascending doses of OPT101.
100 Clinical Results associated with OP LLC
0 Patents (Medical) associated with OP LLC
100 Deals associated with OP LLC
100 Translational Medicine associated with OP LLC